SlideShare a Scribd company logo
America Inventors Act:
Recent Changes to U.S. Patent Law and
              Practice

     University of Washington School of Law
           Advanced Patent Law P545


            Gary M. Myles, Ph.D.
              February 6, 2012
Introduction

• Patent Reform Act of 2011 (a/k/a
  “Leahy-Smith America Invents Act”)
   – Signed into Law by President Obama on
    September 16, 2011
  – Most significant change in U.S. patent law since
    U.S. Patent Act of 1952
Goals of the Act
• “Enhance and encourage innovation
  that improves American
  competitiveness, economic prosperity
  and job growth.” USPTO Commissioner Stoll
• International harmonization
   – Refined definition of prior art
   – Replace first-to-invent with first-inventor-to-file
• Improve the quality of patents
   – Third-party pre-grant submissions
   – Changes to post-grant review
America Invents Act

Timing: Effective Immediately
Prior User Rights
– State Street Bank v. Signature Financial Group
    (CAFC 1998)
     – Court affirmed USPTO and rejected theory that
        “method of doing business” was excluded subject
        matter
–   Prior User Defense (Nov. 29, 1999)
     – 35 USC § 273
        – It shall be a defense to an action for infringement under
           section 271 of this title with respect to any subject matter that
           would otherwise infringe one or more claims for a method [[of
           doing or conducting business]] in the patent being asserted
           against a person, if such person had, acting in good faith,
           actually reduced the subject matter to practice at least 1 year
           before the effective filing date of such patent, and
           commercially used the subject matter before the effective filing
           date of such patent.
Prior User Rights
– Prior User Rights
   • Extends existing defense for business method patents
     to all patents where accused infringer demonstrates
       – Reduction to practice
       – Commercial use
       – One year before patent’s effective filing date
Best Mode Requirement

– Patents not invalid/unenforceable where fail to
  disclose a best mode
Ex parte Re-exam
– Ex parte re-exam remains, but appeals now are
  directly to the Federal Circuit
False Marking and Virtual Marking

  – False Marking and Virtual Marking
     • False marking claim requires competitive injury
     • Expired patent number not false marking
     • Virtual marking OK
         – Associate product/service with internet
           address containing patent number
America Invents Act

Timing: 10-days After Enactment
     (September 26, 2011)
USPTO Fee-setting Authority
• Most PTO fees increase by 15%
• Microentity status gets 75% reduction in fees
   – Individual inventors and small entities with no more
      than four of their own US patent applications, less
      than median household income, and no obligation
      to assign/license to a non-micro entity
   – Institutions of higher education
• Prioritized examination for $4,800 ($2,400 small entity)
   – 4 independent/30 total claims
America Invents Act

Timing: 12-months After Enactment
      (September 16, 2012)
Current Options for Post-Grant Patent
       Review through the PTO

• Reissue
  – Available only to patentees
  – Used to correct errors in specification or
    drawings, or to change scope of claims
     • Can broaden claim scope within two years of
       issuance
     • Can narrow claim scope at any time during
       life of patent
Current Options for Post-Grant Patent
       Review through the PTO

• Ex parte and Inter partes Reexamination
  – Available to patentees and to 3rd parties
  – Analysis of issued patent
     • Based on substantial new question of patentability
     • Based only on patents and printed publications
     • Only relevant to claims
     • Claims cannot be broadened
     • Brought at any time during enforceability of patent
Third-party Submissions
– Pre-issuance, third-party submissions of prior art
   • Showing of relevance + fee
   • Timing restrictions, earlier of:
       – Notice of Allowance, or
       – Later of
           » 6-months post publication, or
           » Date of first rejection
Post-grant review
• Post-grant review
   – Third-party can challenge patent within 9-months of
       issuance
   –   Not limited to invalidity based on prior art
   –   Only for first inventor to file patent applications
Recent Changes to Post-Grant Review

• General Provisions
  – Proceeding before the PTAB to review patent
    validity
  – Based on any available patentability ground
     • contrast with current reexamination – based on
        patents and printed pubs
  – Patentee can cancel claims or add claims to
    substitute challenged claims
  – Claim scope cannot be broadened; no new matter
    may be introduced
Recent Changes to Post-Grant Review

• Timing
  – Initiated within nine months of issuance of
    patent/reissue
  – Review completed within one year
     • possible six-month extension for cause
  – Cannot be initiated if petitioner has brought civil
    action alleging invalidity
Recent Changes to Post-Grant Review

• Threshold showing to initiate action
  –   More likely than not that at least one of
      the claims is unpatentable or
  –   Raises novel/unsettled legal question
      important to other patents/apps
Inter partes review
• Inter partes review
   – After post-grant review period
   – Initiated by third-party where “reasonable
       likelihood” of prevailing
         • Replaces “substantial new question of
           patentability” standard
   –   Patent Trial and Appeal Board must complete
       within 18 months
Recent Changes to Inter Partes Review

• General Provisions
  – Proceeding before PTAB to review patent validity
      • Replaces inter partes reexamination
      • ex parte reexamination remains
  – Basis limited to patents or printed publications and to issues
    of novelty/obviousness under 35 U.S.C. §§ 102/103
  – Patentee can cancel claims or add claims to substitute
    challenged claims
  – Claim scope cannot be broadened; no new matter may be
    introduced
Recent Changes to Inter Partes Review

• Timing
  – Life of patent after later of nine months from issuance
    or termination of post-grant review
  – Review completed within one year
      • possible six-month extension for cause
  – Cannot be initiated if petitioner has brought civil action
    alleging invalidity
  – Proceeding cannot be initiated if petition is filed more
    than six months after petitioner is served with
    complaint alleging infringement of patent
Recent Changes to Inter Partes Review

• Showing
  – Reasonable likelihood petitioner would prevail
    with respect to at least one claim
Benefits of Changes

• Post-Grant Review Procedures
  –   Broaden scope of review by PTO (as opposed to courts)
  –   Reduce costs to challenge patents
  –   Increase patent quality
  –   Expedite PTO review process
  –   Encourage early review and analysis by affected parties
Failure to Obtain Advice from
             Counsel
• Failure to Obtain Advice from Counsel
  – No longer grounds to find that a party
    willfully infringed or intended to induce
    infringement of a patent
  – Codifies Seagate (CAFC)
Errors in Inventorship
• Errors in Inventorship
  – No longer grounds for holding patent
    unenforceable if error is remedied at any
    time w/ supplemental/corrected
    declaration of inventorship
America Invents Act

Timing: 18-months After Enactment
         (March 16, 2013)
First-Inventor-to-File

•   First-to-Invent v. First-Inventor-to-File

                                  First-to-Invent
Conception     RTP                                                 File App
Jan. 1, 2013   Jan. 10, 2013                                       Jul. 1, 2013




                     Conception      RTP             File App
                     Feb. 1, 2013    Feb. 10, 2013   May 1, 2013

                               First-Inventor-to-File
First-Inventor-to-File
•   First-Inventor-to-File
     • 35 U.S.C. § 102(a)-(g) replaced with § 102(a)-(d)
     • Almost absolute novelty requirement
         • One year grace period for any inventor
            publication, public use, offer for sale, or sale
            in the U.S.
         • Does not apply to third party disclosures,
            unless after inventor’s disclosure w/in one
            year grace period
First-Inventor-to-File
•   First-Inventor-to-File
         • 35 U.S.C. § 102(a)(1) replaces § 102(a) and
           (b)
             – Defines prior art
         • 35 U.S.C. § 102(a)(2)
             – Defines “derived” prior art
         • 35 U.S.C. § 102(b)(1) identifies exceptions to
           prior art under § 102(a)(1)
Prior Art
Prior Art
HISTORICALLY – the limits on 102 (i.e., the public policy reasons)
for determining “use” or “on-sale” “in this country” were tied to what
was feasible for an inventor to determine in an era of limited
communications around the world.

EFFECT –
       “Use”, “on sale” or “available to the public” under the Act
now extends this implied knowledge to anywhere in the world.

       In this internet age, this does not seem to be such an
onerous burden.
Prior Art
(a) NOVELTY; PRIOR ART. – A person shall be entitled
  to a patent unless –

(2) the claimed invention was described in a patent
  issued under section 151, or in an application for
  patent published or deemed published under section
  122(b), in which the patent or application, as the case
  may be, names another inventor and was filed before
  the effective filing date of the claimed invention.
Prior Art
• Overall effect –
   – SECRET PRIOR ART –
     • Historically related to 102(e) – a U.S.
     national application.
     • Under the Act – Extends to foreign
     filings
Prior to the CREATE Act
     • Historical Context
        – In re Bass, 474 F.2d 1276 (CCPA 1973)
        – In re Clemens, 622 F.2d 1029 (CCPA 1980)
        – Kimberly-Clark Corp. v. Johnson & Johnson, 745 F.2d
          1437 (CAFC 1984)
            • Non-public, confidential disclosures may be prior
              art under 35 U.S.C. § 102 (g) (prior invention) for
              validity challenges under 35 U.S.C. § 103




35                                                     2/9/2012
Prior to the CREATE Act
     • Historical Context, cont.
        – 1984 Amendment to 35 U.S.C.
           • Excluded from the prior art, for purposes of an
             obviousness challenge, subject matter
             communicated between intra-institutional
             research collaborators which qualifies as prior
             art only under 102(f) or (g), when:
              – At the time of invention
              – Subject matter and the claimed invention were
                  » Owned by the same person, or
                  » Subject to an obligation to assign the same
                    person


36                                                        2/9/2012
Prior to the CREATE Act
     • Historical Context, cont.
        – Oddzon Products v. Just Toys, Inc., 112 F.3d 1396
          (CAFC 1997)
           • Non-public communications between inter-
             institutional research collaborators, where no
             right of ownership existed in a single institution,
             could be used as prior art under 35 U.S.C. §
             102(f) (derived from another) to challenge
             patent validity under 35 U.S.C. § 103




37                                                    2/9/2012
The CREATE Act
     • Cooperative Research and Technology
       Enhancement (CREATE) Act of 2004
       – Rectifies the OddzOn ruling by excluding
         from the prior art, for the purposes of an
         obviousness challenge, “secret” prior art
         resulting from inter-institutional research
         collaborations so long as there is a pre-
         existing (and conforming) agreement



38                                            2/9/2012
The CREATE Act
     • 35 U.S.C. § (c)(1)
        – Subject matter developed by another person
        – Qualifies as prior art only under 35 U.S.C. §
          102(e)(secret), (f)(derived from another), or (g)(prior
          invention)
        – Shall not preclude patentability under 35 U.S.C. § 103
          where
            • Subject matter and claimed invention
            • At the time the claimed invention was made
            • Owned by the same person or subject to an
              obligation of assignment to the same person

39                                                     2/9/2012
The CREATE Act
     – 35 U.S.C. § 103(C)(2)
       – “Owned by the same person”
          • Subject matter developed by another person and a
            claimed invention are deemed owned by the
            same person or subject to an obligation of
            assignment to the same person if:
             – (A) Claimed invention was made by or on behalf of
               parties to a joint research agreement (JRA) in effect on
               or before the date the claimed invention was made;
             – (B) Claimed invention was made as a result of activities
               undertaken within the scope of the JRA; and
             – (C) Application for patent for the claimed invention
               discloses parties to the JRA


40                                                         2/9/2012
The CREATE Act
     – 35 U.S.C. § 103(C)(3)
       – “Joint Research Agreement”
          • “[A] written contract, grant, or cooperative
            agreement entered into by two or more
            persons or entities for the performance of
            experimental, developmental, or research
            work in the field of the claimed invention.”




41                                              2/9/2012
Changes Brought on by the AIA
     • 35 U.S.C. § 103 Amended to Remove 103(c)
     • New 35 U.S.C. § 102 Includes 102(c)
       – Common Ownership Under JRAs
          • Subject matter disclosed and claimed invention
            deemed owned by same person in applying
            102(b)(2)(C) (i.e., prior art exclusion provisions) if:
               – Subject matter disclosed and claimed invention
                 made by parties to a JRA in effect as of the
                 effective filing date of the claimed invention;
               – Claimed invention made within scope of JRA; and
               – Patent application for claimed invention discloses
                 parties to JRA

42                                                      2/9/2012
Best Practices after the AIA
     • Joint Research Agreements
         – Content
             • Must describe general scope of research that encompasses
               later claimed invention
         – Timing
            • Must execute JRA prior to effective filing date of patent
              application disclosing claimed invention
     • Patent Applications
         – Must disclose parties to the JRA
     • Unintended consequences of a pre-JRA non-disclosure agreement
       (NDA)
         – Does not offer the prior art protections of a properly
           drafted and executed JRA
         – For large companies, may open the door for
           impropriety challenges

43                                                             2/9/2012
Derivation Proceedings
– Derivation proceedings under 35 U.S.C. § 135
   • Replace interferences
   • Heard by Patent Trial and Appeal Board
Strategic Considerations
• Promptly file manuscripts and invention
  disclosures as provisional patent applications to
  establish early effective filing date
• Use virtual marking on company web site to
  associate products/services with patent portfolio
• Survey patent landscape to monitor for pre-
  issuance submission and post-grant review
  opportunities
• Consider impact of pre-filing publication within
  one year grace period on international patent
  applications
Stanford v. Roche
              583 F3d 832 (CAFC 2010)
• 1985
   – Cetus develops PCR methods for quantifying HIV
     levels in blood
• 1988
   – Cetus begins collaboration with a laboratory within
     Stanford’s Department of Infectious Diseases to test
     new AIDS drugs
   – Inventor (Dr. Holodniy)
       • Joins Stanford laboratory as a research fellow
       • Signs Copyright and Patent Agreement where he
         “agrees to assign” to Stanford his “right, title and
         interest in” inventions resulting from his
         employment at the University
Stanford v. Roche
            583 F3d 832 (CAFC 2010)
• Inventor begins work on quantifying HIV levels in
  blood using PCR
• Inventor is unfamiliar with PCR technology so he
  performs research at Cetus with Cetus employees
• Cetus requires that Inventor sign a Visitor’s
  Confidentiality Agreement
   – Inventor “will assign and does hereby assign”
     to Cetus his “right, title and interest in each of
     the ideas, inventions and improvements”
     made “as a consequence of [his] access” to
     Cetus
Stanford v. Roche
           583 F3d 832 (CAFC 2010)
• Inventor works with Cetus employees to develop
  testing method
• Inventor returns to Stanford
   – Continues to work on testing method with
     support from an NIH grant
   – Stanford reports finding to the NIH and elects to
     retain title
   – Stanford obtains three patents on inventor’s
     work
Stanford v. Roche
             583 F3d 832 (CAFC 2010)
• 1991
   – Roche acquires Cetus PCR business including rights
     under Visitor’s Confidentiality Agreement
   – Roche produces commercial test
• 2005
   – Stanford sues Roche for patent infringement
• 2010
   – Federal Circuit holds
       • Stanford’s “agrees to assign” language within its
         Copyright and Patent Agreement does not constitute
         a current assignment
       • Cetus’ “will assign and does hereby assign” does
         constitute a current assignment
Stanford v. Roche
           563 U.S. __ (SCOTUS 2011)
• 2010
   – Stanford appeals to U.S. Supreme Court
   – Question Presented for Certiorari
      • "Whether a federal contractor university’s
        statutory right under the Bayh-Dole Act, 35
        U.S.C. §§ 200-212, in inventions arising from
        federally funded research can be terminated
        unilaterally by an individual inventor through a
        separate agreement purporting to assign the
        inventor’s rights to a third party.”
Stanford v. Roche
          563 U.S. __ (SCOTUS 2011)

• 2011
   – Supreme Court upholds time-honored tenet of
     patent law that an inventor owns rights to his/her
     invention
   – Bayh-Dole Act does not affect inventor’s
     ownership rights
   – Breyer dissent
       • Stanford should retain title because “patent law
         appears to have long specified that a present
         assignment of future inventions (as in both
         contracts here) conveyed equitable, but not
         legal, title.”
Questions & Answers

More Related Content

PDF
The American Invents Act (AIA)
PDF
"Your Guide to the America Invents Act (AIA)," The Ohio State Bar Association
PPTX
America Invents Act
PPTX
Patent Law in 2014: Act fast or get left behind
PPTX
PDF
The America Invents Act (AIA)
PPTX
CTO-Patent-Pres
PPT
The AIA_Updated_Nov72013_Jamaica
The American Invents Act (AIA)
"Your Guide to the America Invents Act (AIA)," The Ohio State Bar Association
America Invents Act
Patent Law in 2014: Act fast or get left behind
The America Invents Act (AIA)
CTO-Patent-Pres
The AIA_Updated_Nov72013_Jamaica

What's hot (20)

PPTX
Pitfalls to be Aware of When Working with Inventions Funded Through Governmen...
PDF
Overview on Information Disclosure Statement Practice by Justin Cassell
PPTX
USA Patent Reform
PDF
The Pitch on Patent Reform
PPT
Speeding Up Invalidity Using Procedures at the USPTO
PPTX
Navigating the Patent Prosecution Highway
PDF
The New Patent Act & Major Changes in the Law
PPT
The American Invents Act (AIA): Final USPTO Rules
PDF
The America Invents Act: Final USPTO Rules for 35 U.S.C. 102
PDF
MBHB-Webinar-PTAB-Williams-Schafer-FINAL-02.25.15
PPTX
Patent law and filing procedure
PPT
Patents
PPT
Patent Prosecution Luncheon October 2012
PPTX
Patent law
PDF
Inventorship: Who should be listed as an inventor for a patent?
PPTX
Secret sales- Now a Bar to Obtaining a US Patent.
PPTX
Law of patents
PPT
016 patent infringement
PDF
Patent Reform Act of 2009: Overview of Recent Developments
PPT
From Proof of Concept to Patent: The Nitty Gritty About the Patent Process
Pitfalls to be Aware of When Working with Inventions Funded Through Governmen...
Overview on Information Disclosure Statement Practice by Justin Cassell
USA Patent Reform
The Pitch on Patent Reform
Speeding Up Invalidity Using Procedures at the USPTO
Navigating the Patent Prosecution Highway
The New Patent Act & Major Changes in the Law
The American Invents Act (AIA): Final USPTO Rules
The America Invents Act: Final USPTO Rules for 35 U.S.C. 102
MBHB-Webinar-PTAB-Williams-Schafer-FINAL-02.25.15
Patent law and filing procedure
Patents
Patent Prosecution Luncheon October 2012
Patent law
Inventorship: Who should be listed as an inventor for a patent?
Secret sales- Now a Bar to Obtaining a US Patent.
Law of patents
016 patent infringement
Patent Reform Act of 2009: Overview of Recent Developments
From Proof of Concept to Patent: The Nitty Gritty About the Patent Process
Ad

Viewers also liked (6)

PDF
Us Patent Basics
PPTX
patent act 1970 ppt by srota dawn
PPT
Indian Patent act, 20 feb
PPT
Indian Patent act 1970
PPTX
Indian patent act
PPTX
The patent act
Us Patent Basics
patent act 1970 ppt by srota dawn
Indian Patent act, 20 feb
Indian Patent act 1970
Indian patent act
The patent act
Ad

Similar to America Invents Act: Recent Changes to US Patent Law and Practice (20)

PDF
Leahy Smith America Invents Act
PPTX
AIA - Overview
PDF
Protecting Innovation Under the American Invents Act
PDF
Protecting Innovation Under the America Invents Act
PDF
Important Provisions of The America Invents Act Take Effect in September
PDF
Update on Patent Reform
PDF
The Leahy-Smith American Invents Act: More Complicated than 3D Chess?
PDF
America Invents Act 2011 Dec 15 2011 Slides
PDF
(eBook PDF) Understanding Patent Law, Third Edition 3rd Edition
PDF
U.S. Patent Reform 2011: America Invents Act
PPT
September 2011 Patent Group Lunch
PDF
Changes in Examination Under the America Invents Act
PPTX
European & us patent law module3 2013 updated
PPTX
New Patent System
PDF
Side Bar Sprin 2012
PDF
The New US Patent Law - From a Medical Device Perspective
PPT
Understanding Changes to 35 USC 102 or "First-(Inventor)-To-File
PDF
R Bays - Comparative Patent Registration
PDF
America Invents Act Impact on Asia Technology Cos by Michael Shimokaji
PDF
Protecting Innovation Under the American Invents Act
Leahy Smith America Invents Act
AIA - Overview
Protecting Innovation Under the American Invents Act
Protecting Innovation Under the America Invents Act
Important Provisions of The America Invents Act Take Effect in September
Update on Patent Reform
The Leahy-Smith American Invents Act: More Complicated than 3D Chess?
America Invents Act 2011 Dec 15 2011 Slides
(eBook PDF) Understanding Patent Law, Third Edition 3rd Edition
U.S. Patent Reform 2011: America Invents Act
September 2011 Patent Group Lunch
Changes in Examination Under the America Invents Act
European & us patent law module3 2013 updated
New Patent System
Side Bar Sprin 2012
The New US Patent Law - From a Medical Device Perspective
Understanding Changes to 35 USC 102 or "First-(Inventor)-To-File
R Bays - Comparative Patent Registration
America Invents Act Impact on Asia Technology Cos by Michael Shimokaji
Protecting Innovation Under the American Invents Act

More from Gary M. Myles, Ph.D. (20)

PPTX
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112
PDF
Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curi...
PDF
Myriad Decision May Invalidate Many Patents
PDF
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus ...
PPTX
2017 02-15 uwls-apl_biotech 101
PPTX
2017 01-25 uwls-apl_biotech 112
PPT
2015-11-4_WSU_Defining a Corporate Structure for a Startup Company
PPT
2015-11-4_WSU_Corp Structure & Formation for Start-ups
PDF
Aziz Sancar 2015 Nobel Prize in Chemistry
PDF
13-896; tsac; Biotechnology Industry Organization
PDF
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Ge...
PPTX
Protecting the Inventions of Start-ups
PPT
Preparing for a Financial Audit & Corporate Due Diligence
PDF
Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutica...
PPTX
CASRIP 2012 -- Patenting of Human DNA and Embryos
PPTX
Biotechnology Patent Eligibility
PPT
Les Aia Stanford And Effect Of Valuation 09 Nov11
PDF
Patenting In The Biotech Industry 21 Sep10
PPT
Biotechnology Novelty And Nonobviousness 14 Sep10
PPT
Biotechnology Enablement And Written Description 28 Sep10
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112
Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curi...
Myriad Decision May Invalidate Many Patents
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus ...
2017 02-15 uwls-apl_biotech 101
2017 01-25 uwls-apl_biotech 112
2015-11-4_WSU_Defining a Corporate Structure for a Startup Company
2015-11-4_WSU_Corp Structure & Formation for Start-ups
Aziz Sancar 2015 Nobel Prize in Chemistry
13-896; tsac; Biotechnology Industry Organization
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Ge...
Protecting the Inventions of Start-ups
Preparing for a Financial Audit & Corporate Due Diligence
Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutica...
CASRIP 2012 -- Patenting of Human DNA and Embryos
Biotechnology Patent Eligibility
Les Aia Stanford And Effect Of Valuation 09 Nov11
Patenting In The Biotech Industry 21 Sep10
Biotechnology Novelty And Nonobviousness 14 Sep10
Biotechnology Enablement And Written Description 28 Sep10

America Invents Act: Recent Changes to US Patent Law and Practice

  • 1. America Inventors Act: Recent Changes to U.S. Patent Law and Practice University of Washington School of Law Advanced Patent Law P545 Gary M. Myles, Ph.D. February 6, 2012
  • 2. Introduction • Patent Reform Act of 2011 (a/k/a “Leahy-Smith America Invents Act”) – Signed into Law by President Obama on September 16, 2011 – Most significant change in U.S. patent law since U.S. Patent Act of 1952
  • 3. Goals of the Act • “Enhance and encourage innovation that improves American competitiveness, economic prosperity and job growth.” USPTO Commissioner Stoll • International harmonization – Refined definition of prior art – Replace first-to-invent with first-inventor-to-file • Improve the quality of patents – Third-party pre-grant submissions – Changes to post-grant review
  • 4. America Invents Act Timing: Effective Immediately
  • 5. Prior User Rights – State Street Bank v. Signature Financial Group (CAFC 1998) – Court affirmed USPTO and rejected theory that “method of doing business” was excluded subject matter – Prior User Defense (Nov. 29, 1999) – 35 USC § 273 – It shall be a defense to an action for infringement under section 271 of this title with respect to any subject matter that would otherwise infringe one or more claims for a method [[of doing or conducting business]] in the patent being asserted against a person, if such person had, acting in good faith, actually reduced the subject matter to practice at least 1 year before the effective filing date of such patent, and commercially used the subject matter before the effective filing date of such patent.
  • 6. Prior User Rights – Prior User Rights • Extends existing defense for business method patents to all patents where accused infringer demonstrates – Reduction to practice – Commercial use – One year before patent’s effective filing date
  • 7. Best Mode Requirement – Patents not invalid/unenforceable where fail to disclose a best mode
  • 8. Ex parte Re-exam – Ex parte re-exam remains, but appeals now are directly to the Federal Circuit
  • 9. False Marking and Virtual Marking – False Marking and Virtual Marking • False marking claim requires competitive injury • Expired patent number not false marking • Virtual marking OK – Associate product/service with internet address containing patent number
  • 10. America Invents Act Timing: 10-days After Enactment (September 26, 2011)
  • 11. USPTO Fee-setting Authority • Most PTO fees increase by 15% • Microentity status gets 75% reduction in fees – Individual inventors and small entities with no more than four of their own US patent applications, less than median household income, and no obligation to assign/license to a non-micro entity – Institutions of higher education • Prioritized examination for $4,800 ($2,400 small entity) – 4 independent/30 total claims
  • 12. America Invents Act Timing: 12-months After Enactment (September 16, 2012)
  • 13. Current Options for Post-Grant Patent Review through the PTO • Reissue – Available only to patentees – Used to correct errors in specification or drawings, or to change scope of claims • Can broaden claim scope within two years of issuance • Can narrow claim scope at any time during life of patent
  • 14. Current Options for Post-Grant Patent Review through the PTO • Ex parte and Inter partes Reexamination – Available to patentees and to 3rd parties – Analysis of issued patent • Based on substantial new question of patentability • Based only on patents and printed publications • Only relevant to claims • Claims cannot be broadened • Brought at any time during enforceability of patent
  • 15. Third-party Submissions – Pre-issuance, third-party submissions of prior art • Showing of relevance + fee • Timing restrictions, earlier of: – Notice of Allowance, or – Later of » 6-months post publication, or » Date of first rejection
  • 16. Post-grant review • Post-grant review – Third-party can challenge patent within 9-months of issuance – Not limited to invalidity based on prior art – Only for first inventor to file patent applications
  • 17. Recent Changes to Post-Grant Review • General Provisions – Proceeding before the PTAB to review patent validity – Based on any available patentability ground • contrast with current reexamination – based on patents and printed pubs – Patentee can cancel claims or add claims to substitute challenged claims – Claim scope cannot be broadened; no new matter may be introduced
  • 18. Recent Changes to Post-Grant Review • Timing – Initiated within nine months of issuance of patent/reissue – Review completed within one year • possible six-month extension for cause – Cannot be initiated if petitioner has brought civil action alleging invalidity
  • 19. Recent Changes to Post-Grant Review • Threshold showing to initiate action – More likely than not that at least one of the claims is unpatentable or – Raises novel/unsettled legal question important to other patents/apps
  • 20. Inter partes review • Inter partes review – After post-grant review period – Initiated by third-party where “reasonable likelihood” of prevailing • Replaces “substantial new question of patentability” standard – Patent Trial and Appeal Board must complete within 18 months
  • 21. Recent Changes to Inter Partes Review • General Provisions – Proceeding before PTAB to review patent validity • Replaces inter partes reexamination • ex parte reexamination remains – Basis limited to patents or printed publications and to issues of novelty/obviousness under 35 U.S.C. §§ 102/103 – Patentee can cancel claims or add claims to substitute challenged claims – Claim scope cannot be broadened; no new matter may be introduced
  • 22. Recent Changes to Inter Partes Review • Timing – Life of patent after later of nine months from issuance or termination of post-grant review – Review completed within one year • possible six-month extension for cause – Cannot be initiated if petitioner has brought civil action alleging invalidity – Proceeding cannot be initiated if petition is filed more than six months after petitioner is served with complaint alleging infringement of patent
  • 23. Recent Changes to Inter Partes Review • Showing – Reasonable likelihood petitioner would prevail with respect to at least one claim
  • 24. Benefits of Changes • Post-Grant Review Procedures – Broaden scope of review by PTO (as opposed to courts) – Reduce costs to challenge patents – Increase patent quality – Expedite PTO review process – Encourage early review and analysis by affected parties
  • 25. Failure to Obtain Advice from Counsel • Failure to Obtain Advice from Counsel – No longer grounds to find that a party willfully infringed or intended to induce infringement of a patent – Codifies Seagate (CAFC)
  • 26. Errors in Inventorship • Errors in Inventorship – No longer grounds for holding patent unenforceable if error is remedied at any time w/ supplemental/corrected declaration of inventorship
  • 27. America Invents Act Timing: 18-months After Enactment (March 16, 2013)
  • 28. First-Inventor-to-File • First-to-Invent v. First-Inventor-to-File First-to-Invent Conception RTP File App Jan. 1, 2013 Jan. 10, 2013 Jul. 1, 2013 Conception RTP File App Feb. 1, 2013 Feb. 10, 2013 May 1, 2013 First-Inventor-to-File
  • 29. First-Inventor-to-File • First-Inventor-to-File • 35 U.S.C. § 102(a)-(g) replaced with § 102(a)-(d) • Almost absolute novelty requirement • One year grace period for any inventor publication, public use, offer for sale, or sale in the U.S. • Does not apply to third party disclosures, unless after inventor’s disclosure w/in one year grace period
  • 30. First-Inventor-to-File • First-Inventor-to-File • 35 U.S.C. § 102(a)(1) replaces § 102(a) and (b) – Defines prior art • 35 U.S.C. § 102(a)(2) – Defines “derived” prior art • 35 U.S.C. § 102(b)(1) identifies exceptions to prior art under § 102(a)(1)
  • 32. Prior Art HISTORICALLY – the limits on 102 (i.e., the public policy reasons) for determining “use” or “on-sale” “in this country” were tied to what was feasible for an inventor to determine in an era of limited communications around the world. EFFECT – “Use”, “on sale” or “available to the public” under the Act now extends this implied knowledge to anywhere in the world. In this internet age, this does not seem to be such an onerous burden.
  • 33. Prior Art (a) NOVELTY; PRIOR ART. – A person shall be entitled to a patent unless – (2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was filed before the effective filing date of the claimed invention.
  • 34. Prior Art • Overall effect – – SECRET PRIOR ART – • Historically related to 102(e) – a U.S. national application. • Under the Act – Extends to foreign filings
  • 35. Prior to the CREATE Act • Historical Context – In re Bass, 474 F.2d 1276 (CCPA 1973) – In re Clemens, 622 F.2d 1029 (CCPA 1980) – Kimberly-Clark Corp. v. Johnson & Johnson, 745 F.2d 1437 (CAFC 1984) • Non-public, confidential disclosures may be prior art under 35 U.S.C. § 102 (g) (prior invention) for validity challenges under 35 U.S.C. § 103 35 2/9/2012
  • 36. Prior to the CREATE Act • Historical Context, cont. – 1984 Amendment to 35 U.S.C. • Excluded from the prior art, for purposes of an obviousness challenge, subject matter communicated between intra-institutional research collaborators which qualifies as prior art only under 102(f) or (g), when: – At the time of invention – Subject matter and the claimed invention were » Owned by the same person, or » Subject to an obligation to assign the same person 36 2/9/2012
  • 37. Prior to the CREATE Act • Historical Context, cont. – Oddzon Products v. Just Toys, Inc., 112 F.3d 1396 (CAFC 1997) • Non-public communications between inter- institutional research collaborators, where no right of ownership existed in a single institution, could be used as prior art under 35 U.S.C. § 102(f) (derived from another) to challenge patent validity under 35 U.S.C. § 103 37 2/9/2012
  • 38. The CREATE Act • Cooperative Research and Technology Enhancement (CREATE) Act of 2004 – Rectifies the OddzOn ruling by excluding from the prior art, for the purposes of an obviousness challenge, “secret” prior art resulting from inter-institutional research collaborations so long as there is a pre- existing (and conforming) agreement 38 2/9/2012
  • 39. The CREATE Act • 35 U.S.C. § (c)(1) – Subject matter developed by another person – Qualifies as prior art only under 35 U.S.C. § 102(e)(secret), (f)(derived from another), or (g)(prior invention) – Shall not preclude patentability under 35 U.S.C. § 103 where • Subject matter and claimed invention • At the time the claimed invention was made • Owned by the same person or subject to an obligation of assignment to the same person 39 2/9/2012
  • 40. The CREATE Act – 35 U.S.C. § 103(C)(2) – “Owned by the same person” • Subject matter developed by another person and a claimed invention are deemed owned by the same person or subject to an obligation of assignment to the same person if: – (A) Claimed invention was made by or on behalf of parties to a joint research agreement (JRA) in effect on or before the date the claimed invention was made; – (B) Claimed invention was made as a result of activities undertaken within the scope of the JRA; and – (C) Application for patent for the claimed invention discloses parties to the JRA 40 2/9/2012
  • 41. The CREATE Act – 35 U.S.C. § 103(C)(3) – “Joint Research Agreement” • “[A] written contract, grant, or cooperative agreement entered into by two or more persons or entities for the performance of experimental, developmental, or research work in the field of the claimed invention.” 41 2/9/2012
  • 42. Changes Brought on by the AIA • 35 U.S.C. § 103 Amended to Remove 103(c) • New 35 U.S.C. § 102 Includes 102(c) – Common Ownership Under JRAs • Subject matter disclosed and claimed invention deemed owned by same person in applying 102(b)(2)(C) (i.e., prior art exclusion provisions) if: – Subject matter disclosed and claimed invention made by parties to a JRA in effect as of the effective filing date of the claimed invention; – Claimed invention made within scope of JRA; and – Patent application for claimed invention discloses parties to JRA 42 2/9/2012
  • 43. Best Practices after the AIA • Joint Research Agreements – Content • Must describe general scope of research that encompasses later claimed invention – Timing • Must execute JRA prior to effective filing date of patent application disclosing claimed invention • Patent Applications – Must disclose parties to the JRA • Unintended consequences of a pre-JRA non-disclosure agreement (NDA) – Does not offer the prior art protections of a properly drafted and executed JRA – For large companies, may open the door for impropriety challenges 43 2/9/2012
  • 44. Derivation Proceedings – Derivation proceedings under 35 U.S.C. § 135 • Replace interferences • Heard by Patent Trial and Appeal Board
  • 45. Strategic Considerations • Promptly file manuscripts and invention disclosures as provisional patent applications to establish early effective filing date • Use virtual marking on company web site to associate products/services with patent portfolio • Survey patent landscape to monitor for pre- issuance submission and post-grant review opportunities • Consider impact of pre-filing publication within one year grace period on international patent applications
  • 46. Stanford v. Roche 583 F3d 832 (CAFC 2010) • 1985 – Cetus develops PCR methods for quantifying HIV levels in blood • 1988 – Cetus begins collaboration with a laboratory within Stanford’s Department of Infectious Diseases to test new AIDS drugs – Inventor (Dr. Holodniy) • Joins Stanford laboratory as a research fellow • Signs Copyright and Patent Agreement where he “agrees to assign” to Stanford his “right, title and interest in” inventions resulting from his employment at the University
  • 47. Stanford v. Roche 583 F3d 832 (CAFC 2010) • Inventor begins work on quantifying HIV levels in blood using PCR • Inventor is unfamiliar with PCR technology so he performs research at Cetus with Cetus employees • Cetus requires that Inventor sign a Visitor’s Confidentiality Agreement – Inventor “will assign and does hereby assign” to Cetus his “right, title and interest in each of the ideas, inventions and improvements” made “as a consequence of [his] access” to Cetus
  • 48. Stanford v. Roche 583 F3d 832 (CAFC 2010) • Inventor works with Cetus employees to develop testing method • Inventor returns to Stanford – Continues to work on testing method with support from an NIH grant – Stanford reports finding to the NIH and elects to retain title – Stanford obtains three patents on inventor’s work
  • 49. Stanford v. Roche 583 F3d 832 (CAFC 2010) • 1991 – Roche acquires Cetus PCR business including rights under Visitor’s Confidentiality Agreement – Roche produces commercial test • 2005 – Stanford sues Roche for patent infringement • 2010 – Federal Circuit holds • Stanford’s “agrees to assign” language within its Copyright and Patent Agreement does not constitute a current assignment • Cetus’ “will assign and does hereby assign” does constitute a current assignment
  • 50. Stanford v. Roche 563 U.S. __ (SCOTUS 2011) • 2010 – Stanford appeals to U.S. Supreme Court – Question Presented for Certiorari • "Whether a federal contractor university’s statutory right under the Bayh-Dole Act, 35 U.S.C. §§ 200-212, in inventions arising from federally funded research can be terminated unilaterally by an individual inventor through a separate agreement purporting to assign the inventor’s rights to a third party.”
  • 51. Stanford v. Roche 563 U.S. __ (SCOTUS 2011) • 2011 – Supreme Court upholds time-honored tenet of patent law that an inventor owns rights to his/her invention – Bayh-Dole Act does not affect inventor’s ownership rights – Breyer dissent • Stanford should retain title because “patent law appears to have long specified that a present assignment of future inventions (as in both contracts here) conveyed equitable, but not legal, title.”